Continued improvement in financial performance Cash and short-term investments of CHF 262.8 million Guidance on isavuconazole phase 3 topline data…
BAL30072 current multiple ascending dose study reached maximum tolerated dose Further development, including combination studies with carbapenems, planned under BARDA…